|Articles|January 20, 2015

Orphan Drug Prices Facing Increased Scrutiny

Author(s)Applied Clinical Trials Editorial Staff

With the US Food and Drug Administration (FDA) approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny.

Research and consulting firm GlobalData says the FDA approved an all-time record number of 17 orphan drugs during 2014. This out of the total of 41 new molecular entities approved by the FDA last year. The report from GlobalData further stated that while the rare disease sector may appear to be increasingly lucrative for pharmaceutical companies, some orphan drug prices have recently reached new unprecedented levels and their affordability has become a significant issue for payers.

Read the full text here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Orphan Drug Prices Facing Increased Scrutiny

Related Content

Beyond Patient Centricity: What Rare Disease Research Gets Right

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

Why Time Savings Is the Largest Driver of RBQM's Financial Value

Trending on Applied Clinical Trials Online

Beyond Patient Centricity: What Rare Disease Research Gets Right

AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective

Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files